One biopharmaceutical player that insiders are jumping into big here is
Achillion Pharmaceuticals(
ACHN), which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. Insiders are buying this stock into massive weakness, since shares are off sharply by 67% so far in 2013.
Achillion Pharmaceuticals has a market cap of $246.43 million and an enterprise value of $136.34 million. This stock trades at a premium valuation, with a price-to-sales of 2,244 and a price-to-book of 1.50. Its estimated growth rate for this year is -14.1%, and for next year it's pegged at -15.1%. This is a cash-rich company, since the total cash position on its balance sheet is $133.82 million and its total debt is just $525,000.
A beneficial owner just
bought 2.8 million shares, or about $8.35 million worth of stock, at $2.96 to $3.01 per share.
From a technical perspective, ACHN is currently trending just below both its 50-day and 200-day moving averages, which is bearish. This stock recently gapped down sharply from around $7.50 to below $3 a share with heavy downside volume. Following that gap down, shares of ACHN have continued to trend lower with the stock printing a new 52-week low today. This move has pushed shares of ACHN into extremely oversold territory, since its current relative strength index reading is 18.08. Oversold can always get more oversold, but it's also an area where a stock can bounce sharply higher from if the buyers step back in.
If you're bullish on ACHN, then look for long-biased trades as long as this stock is trending above $2.50 and then once it breaks out above some near-term overhead resistance levels at $2.85 to $3 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 2.10 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high of $3.62 a share.